What did @lizparry actually say?
In a video now past 313,000 views, @lizparry explained that she skipped the prescription route entirely because the cost of tirzepatide was too high. Instead, she ordered what she calls "the peptide version" — a powder you mix at home — from a vendor she found through Reddit. She described the reconstitution process, noted the site can't legally sell it "for human consumption," and then recommended the vendor to anyone watching. Her words: "I would recommend it to anybody and every single time I order, it will be from them."
She named a specific website. She described the packaging, the lab testing posted online, and the price as roughly a quarter of what a legitimate prescription costs. The framing throughout was enthusiastic and instructional, which is exactly why this needs a close look.
Does the science back this up?
On the pharmacology, she's not entirely wrong — tirzepatide is a peptide, and the active molecule can theoretically be produced as a lyophilized (freeze-dried) powder. The problem is that "theoretically" and "safely administered at home from a vendor you found on Reddit" are not the same sentence.
Tirzepatide's approval by the FDA (2022, for type 2 diabetes as Mounjaro; 2023, for obesity as Zepbound) was based on trials with pharmaceutical-grade manufacturing, verified dosing, sterility testing, and controlled delivery systems. A 2023 paper by FrÃas et al. in The Lancet showed the dose-response relationship in tirzepatide is steep — meaning small errors in reconstitution or measurement produce meaningfully different outcomes, including hypoglycemia and severe GI events.
She also mentioned reconstituting with "bacteria stata water" — almost certainly bacteriostatic water, which is the correct diluent. Credit where it's due: she got that part right. But correct diluent from an incorrect source in a non-sterile home environment still carries serious contamination risk. The FDA has issued multiple warnings about compounded semaglutide and GLP-1 peptides from unregulated suppliers, citing contamination and incorrect dosing (FDA Drug Safety Communication, 2024).
What did they get wrong (or right)?
She got the gray-market framing right, at least technically. Vendors who sell research peptides label them "not for human consumption" precisely to sidestep FDA oversight. That's accurate. What she got wrong is presenting this legal technicality as a reasonable workaround rather than a genuine warning sign.
The claim that lab testing posted on a vendor's website is meaningful quality assurance is misleading. Those certificates of analysis are typically self-reported or sourced from third parties with no regulatory accountability. The FDA does not inspect these suppliers. A 2023 analysis by Valisure (an independent pharmacy testing lab) found that some compounded GLP-1 products contained incorrect active ingredient concentrations ranging from 60% to 130% of the labeled dose. A 30% overdose of tirzepatide is not a minor inconvenience.
She did not claim tirzepatide cures PCOS or endometriosis, which is worth noting. The hashtags suggest that's the underlying health context, but she kept her claims to price and convenience. That's actually more restrained than many creators in this space.
What should you actually know?
Buying injectable peptides from an unregulated online vendor and self-injecting them is not a safe workaround to high drug prices. It is an uncontrolled experiment on yourself with no medical supervision, no verified dosing, and no legal recourse if something goes wrong.
The cost barrier she's describing is real and worth taking seriously. Tirzepatide without insurance can exceed $1,000 per month. Telehealth platforms and compounding pharmacies operating under FDA-registered facilities do offer lower-cost options that are at least within a regulated framework. FDA-registered 503B outsourcing facilities, for example, operate under mandatory inspection and sterility requirements — the vendors @lizparry is describing do not.
If you have PCOS or endometriosis and are considering GLP-1 therapy, there is emerging (not yet definitive) evidence of benefit. A 2024 study by Morin et al. in Fertility and Sterility found semaglutide improved metabolic markers in women with PCOS. But that evidence was built on pharmaceutical-grade drugs at verified doses, not reconstituted powders from Reddit-vetted vendors.
The bottom line: the price problem is legitimate. The solution she's offering is not.